Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981903 · ClinicalTrials.gov registry record · Phase 2
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT00981903 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 131 participants.
The verdict
NCT00981903, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
Interventions
- DRUG Tinzaparin sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2005-07 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00981903
The ClinicalTrials.gov registry entry for NCT00981903 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tinzaparin sodium is the first listed.
NCT00981903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00981903 about?
NCT00981903 is a clinical study titled "Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer". In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
What is the current status of trial NCT00981903?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2005-07. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00981903?
The interventions under investigation include: Tinzaparin sodium (DRUG).
Who is sponsoring clinical trial NCT00981903?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.